Impaired β-arrestin recruitment and reduced desensitization by non-catechol agonists of the D1 dopamine receptor
Dopamine receptor agonists are used for the treatment of various psychiatric diseases. Here, the authors screen approximately three million compounds and identify a novel class of D1R agonists that do not have a catechol scaffold and possess promising pharmacokinetic properties.
Guardado en:
Autores principales: | David L. Gray, John A. Allen, Scot Mente, Rebecca E. O’Connor, George J. DeMarco, Ivan Efremov, Patrick Tierney, Dmitri Volfson, Jennifer Davoren, Edward Guilmette, Michelle Salafia, Rouba Kozak, Michael D. Ehlers |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2018
|
Materias: | |
Acceso en línea: | https://doaj.org/article/8a74eb3e0a2d4c1fa0ce2b3e319fdc9f |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
The Effects of a Novel Non-catechol Dopamine Partial Agonist on Working Memory in the Aged Rhesus Monkey
por: Tara L. Moore, et al.
Publicado: (2021) -
Crystal structure of dopamine D1 receptor in complex with G protein and a non-catechol agonist
por: Bingfa Sun, et al.
Publicado: (2021) -
Potential link between genetic polymorphisms of catechol-O-methyltransferase and dopamine receptors and treatment efficacy of risperidone on schizophrenia
por: Han JY, et al.
Publicado: (2017) -
Ang-(1-7) is an endogenous β-arrestin-biased agonist of the AT1 receptor with protective action in cardiac hypertrophy
por: Larissa B. Teixeira, et al.
Publicado: (2017) -
Agonist dependency of the second phase access of β-arrestin 2 to the heteromeric µ-V1b receptor
por: Nuttawadee Ngamlertwong, et al.
Publicado: (2021)